Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells $11,298.00 in Stock

Key Points

• Adam Scott Levy, CFO of Mineralys Therapeutics, sold a total of 807 shares at an average price of $14.00, reducing his total ownership to 192,859 shares valued at approximately $2.7 million.
• Mineralys Therapeutics’ stock showed a price increase reaching $14.49 on the most recent trading day, with a market cap of $944.46 million and a 52-week price range between $8.24 and $18.38.
• Recent analyst ratings include a downgrade to "sell" from Wall Street Zen and a "buy" rating from Guggenheim, indicating mixed sentiments about the company's performance.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CFO Adam Scott Levy sold 807 shares of the stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $14.00, for a total value of $11,298.00. Following the completion of the transaction, the chief financial officer owned 192,859 shares of the company's stock, valued at approximately $2,700,026. This trade represents a 0.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Adam Scott Levy also recently made the following trade(s):

• On Wednesday, July 30th, Adam Scott Levy sold 59,925 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $14.76, for a total value of $884,493.00.
• On Monday, July 28th, Adam Scott Levy sold 12,946 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $14.04, for a total value of $181,761.84.
• On Friday, July 11th, Adam Scott Levy sold 10,758 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $14.45, for a total value of $155,453.10.

Mineralys Therapeutics Stock Performance

Shares of MLYS traded down $0.49 during trading hours on Friday, hitting $13.66. The company had a trading volume of 1,107,843 shares, compared to its average volume of 637,447. The firm has a fifty day moving average price of $14.52 and a 200-day moving average price of $13.27. The stock has a market capitalization of $890.36 million, a price-to-earnings ratio of -3.66 and a beta of -0.29. Mineralys Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $18.38.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.23. Research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on MLYS shares. Wall Street Zen downgraded Mineralys Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Guggenheim set a $48.00 target price on Mineralys Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and issued a $42.00 price target on shares of Mineralys Therapeutics in a research report on Tuesday, June 17th. Finally, Jefferies Financial Group assumed coverage on Mineralys Therapeutics in a research report on Tuesday, June 10th. They issued a "hold" rating and a $15.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $32.25.

Institutional Investors Weigh In On Mineralys Therapeutics

Several institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Mineralys Therapeutics by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company's stock valued at $271,000 after buying an additional 702 shares during the last quarter. AlphaQuest LLC boosted its position in shares of Mineralys Therapeutics by 4.6% during the first quarter. AlphaQuest LLC now owns 15,925 shares of the company's stock valued at $253,000 after buying an additional 703 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Mineralys Therapeutics by 51.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company's stock valued at $34,000 after buying an additional 850 shares during the last quarter. SBI Securities Co. Ltd. boosted its position in shares of Mineralys Therapeutics by 297.5% during the first quarter. SBI Securities Co. Ltd. now owns 1,590 shares of the company's stock valued at $25,000 after buying an additional 1,190 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Mineralys Therapeutics by 0.7% in the fourth quarter. Northern Trust Corp now owns 246,113 shares of the company's stock worth $3,030,000 after purchasing an additional 1,688 shares during the last quarter. 84.46% of the stock is owned by hedge funds and other institutional investors.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.